The Decipher Bladder test identifies aggressive bladder cancer, aiding in treatment decisions beyond initial clinical staging. Non-luminal tumors in NMIBC show higher upstaging rates to MIBC and ...
In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...
In a discovery that could improve the survival of bladder cancer patients, Northwestern Medicine scientists have developed a biomarker signature test to predict which tumors will respond to ...
Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder Genomic ...
Early detection of bladder cancer can improve clinical outcomes and survival rates, similar to other cancers. One current area of research involves looking at cell mutations in areas where cancer may ...
BIRMINGHAM, England--(BUSINESS WIRE)--Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, and the University of Birmingham have partnered to develop a ...
In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results